Ex vivo bone marrow purging with oligonucleotides

Antisense and Nucleic Acid Drug Development

Volumn 7, Issue 3, 1997, Pages 251-255

  Bergan, Raymond C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE;

BONE MARROW PURGING; CONFERENCE PAPER; DRUG TARGETING; DRUG UPTAKE; ELECTROPORATION; HEMATOPOIESIS; HUMAN; NONHUMAN; PRIORITY JOURNAL;

EID: 0030752136     PISSN: 10872906     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.1.1997.7.251     Document Type: Conference Paper

References (6)

1. BELTINGER, C., SARAGOVI, H.U., SMITH, K.M., LESAUTEUR, L., SHAH, N., DEDIONISIO, L., CHRISTENSEN, L., RAIBLE, A., JARETT, L., and GEWIRTZ, A.M. (1995). Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J. Clin. Invest. 95, 1814-1823.
2. bcr-abl tyrosine kinase autophosphorylation by oligodeoxynucleotides of defined sequence and backbone structure. Nucleic Acids Res. 22, 2150-2154.
3. BERGAN, R., CONNELL, Y., FAHMY, B., and NECKERS, L. (1993). Electroporation enhances c-myc antisense oligodeoxynucleotide efficacy. Nucleic Acids Res. 21, 3567-3573.
4. BERGAN, R., HAKIM, F., SCHWARTZ, G.N., KYLE, E., CEPADA, R., SZABO, J., FOWLER, D., GRESS, R., and NECKERS, L. (1996a). Electroporation of synthetic oligodeoxynucleotides: A novel technique for ex vivo bone marrow purging. Blood 88, 731-741.
5. BERGAN, R.C., KYLE, E., CONNELL, Y., and NECKERS, L. (1995). Inhibition of protein-tyrosine kinase activity in intact cells by the aptameric action of oligodeoxynucleotides. Antisense Res. Dev. 5, 33-38.
6. ZAMECNIK, P.C., and STEPHENSON, M.L. (1978). Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. USA 75, 280-285.